Premium
Plasma level of the macrophage‐derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease
Author(s) -
Møller Holger Jon,
Fost Maaike de,
Aerts Hans,
Hollak Carla,
Moestrup Søren Kragh
Publication year - 2004
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1046/j.0902-4441.2003.00193.x
Subject(s) - cd163 , macrophage , disease , medicine , monocyte , immunology , percentile , gastroenterology , endocrinology , chemistry , biochemistry , in vitro , statistics , mathematics
Recently, soluble CD163 (sCD163) has been identified as a macrophage/monocyte‐specific plasma protein and increased concentrations have been measured in patients with infection and myeloid leukaemia. In the present study we investigated the levels of sCD163 in patients with Gaucher's disease, an inherited lysosomal storage disorder characterised by hepato‐ and spleno‐megaly due to excessive accumulation of macrophages. The sCD163 plasma levels, median (25–75 percentiles), were far above the levels in normal subjects [7.1 mg/L (4.8–10.3) vs. 1.9 mg/L (1.5–2.4), P < 0.0001]. After initiation of enzyme supplementation therapy, the sCD163 levels were significantly reduced [4.7 mg/L (3.2–6.6), P = 0.0004]. sCD163 correlated with disease severity (rho = 0.43, P < 0.0061) and chitotriosidase activity (rho = 0.71, P > 0.0001). This study further establishes that sCD163 may be a valuable laboratory parameter in monitoring disease with increased macrophage activity.